
    
      This is a Phase 1b multicenter, randomized, double-blind, placebo-controlled multiple dose
      study designed to evaluate the safety and tolerability of SER-287, and to evaluate the
      microbiome alterations and pharmacodynamics associated with two dosing regimens of SER-287 in
      adult subjects with active mild-to-moderate ulcerative colitis (UC).
    
  